{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:52:23Z","timestamp":1790797943197,"version":"4.1.0"},"reference-count":154,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T00:00:00Z","timestamp":1626825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:p>Immunotherapy has moved to the forefront of modern oncologic treatment in the past few decades. Various forms of immunotherapy currently are emerging, including oncolytic viruses. In this therapy, viruses are engineered to selectively propagate in tumor cells and reduce toxicity for non-neoplastic tissues. Adenovirus is one of the most frequently employed oncolytic viruses because of its capacity in tumor cell lysis and immune response stimulation. Upregulation of immunostimulatory signals induced by oncolytic adenoviruses (OAds) might significantly remove local immune suppression and amplify antitumor immune responses. Existing genetic engineering technology allows us to design OAds with increasingly better tumor tropism, selectivity, and antitumor efficacy. Several promising strategies to modify the genome of OAds have been applied: capsid modifications, small deletions in the pivotal viral genes, insertion of tumor-specific promoters, and addition of immunostimulatory transgenes. OAds armed with tumor-associated antigen (TAA) transgenes as cancer vaccines provide additional therapeutic strategies to trigger tumor-specific immunity. Furthermore, the combination of OAds and immune checkpoint inhibitors (ICIs) increases clinical benefit as evidence shown in completed and ongoing clinical trials, especially in the combination of OAds with antiprogrammed death 1\/programed death ligand 1 (PD-1\/PD-L1) therapy. Despite remarkable antitumor potency, oncolytic adenovirus immunotherapy is confronted with tough challenges such as antiviral immune response and obstruction of tumor microenvironment (TME). In this review, we focus on genomic modification strategies of oncolytic adenoviruses and applications of OAds in cancer immunotherapy.<\/jats:p>","DOI":"10.3389\/fmicb.2021.707290","type":"journal-article","created":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T10:10:22Z","timestamp":1626862222000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":64,"title":["Oncolytic Adenovirus: Prospects for Cancer Immunotherapy"],"prefix":"10.3389","volume":"12","author":[{"given":"Yaqi","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huibo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haohan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyu","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.05.010","article-title":"SnapShot: Immune Checkpoint Inhibitors.","volume":"31","author":"Abril-Rodriguez","year":"2017","journal-title":"Cancer Cell"},{"key":"B2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1093\/neuonc\/noz175.032","article-title":"Interim results of a phase II multi-center study of oncolytic adenovirus DNX-2401 with pembrolizumab for recurrent glioblastoma; captive study (KEYNOTE-192).","volume":"21","author":"Aiken","year":"2019","journal-title":"Neuro Oncol."},{"key":"B3","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1002\/eji.1830240943","article-title":"Molecular and biological characterization of human 4-1BB and its ligand.","volume":"24","author":"Alderson","year":"1994","journal-title":"Eur. J. Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.tips.2012.04.005","article-title":"Adenovirus receptors: implications for targeting of viral vectors.","volume":"33","author":"Arnberg","year":"2012","journal-title":"Trends Pharmacol. Sci."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08599-y","article-title":"Diversity within the adenovirus fiber knob hypervariable loops influences primary receptor interactions.","volume":"10","author":"Baker","year":"2019","journal-title":"Nat. Commun."},{"key":"B7","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s00262-015-1706-4","article-title":"Extended evaluation of a phase 1\/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer.","volume":"64","author":"Balint","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"key":"B8","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41417-018-0019-0","article-title":"Regulated intratumoral expression of IL-12 using a RheoSwitch Therapeutic System (RTS) gene switch as gene therapy for the treatment of glioma.","volume":"25","author":"Barrett","year":"2018","journal-title":"Cancer Gene Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ymthe.2006.01.010","article-title":"Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells.","volume":"14","author":"Bauerschmitz","year":"2006","journal-title":"Mol. Ther."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002374","article-title":"Phase I study of a multitargeted recombinant Ad5 PSA\/MUC-1\/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC).","volume":"9","author":"Bilusic","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1126\/science.274.5286.373","article-title":"An adenovirus mutant that replicates selectively in p53-deficient human tumor cells.","volume":"274","author":"Bischoff","year":"1996","journal-title":"Science"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1002\/ijc.29536","article-title":"Treatment of melanoma with a serotype 5\/3 chimeric oncolytic adenovirus coding for GM-CSF: Results in vitro, in rodents and in humans.","volume":"137","author":"Bramante","year":"2015","journal-title":"Int. J. Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1016\/j.juro.2012.07.097","article-title":"A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer.","volume":"188","author":"Burke","year":"2012","journal-title":"J. Urol."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01786","article-title":"The Oncolytic Virus in Cancer Diagnosis and Treatment.","volume":"10","author":"Cao","year":"2020","journal-title":"Front. Oncol."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1412902","article-title":"TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade.","volume":"7","author":"Cervera-Carrascon","year":"2018","journal-title":"Oncoimmunology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1729300","article-title":"Oncolytic poxvirus CF33-hNIS-\u0394F14.5 favorably modulates tumor immune microenvironment and works synergistically with anti-PD-L1 antibody in a triple-negative breast cancer model.","volume":"9","author":"Chaurasiya","year":"2020","journal-title":"Oncoimmunology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3109\/08830185.2013.823420","article-title":"Adenoviruses types, cell receptors and local innate cytokines in adenovirus infection.","volume":"33","author":"Chen","year":"2014","journal-title":"Int. Rev. Immunol."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2011.03.021","article-title":"Enhanced antitumor efficacy of a novel fiber chimeric oncolytic adenovirus expressing p53 on hepatocellular carcinoma.","volume":"307","author":"Chen","year":"2011","journal-title":"Cancer Lett."},{"key":"B19","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood-2017-06-741041","article-title":"Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies.","volume":"131","author":"Chester","year":"2018","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07136-7","article-title":"Structure of the 4-1BB\/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab.","volume":"9","author":"Chin","year":"2018","journal-title":"Nat. Commun."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw5680","article-title":"Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial.","volume":"11","author":"Chiocca","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1002\/ijc.29592","article-title":"Potent and long-term antiangiogenic efficacy mediated by FP3-expressing oncolytic adenovirus.","volume":"137","author":"Choi","year":"2015","journal-title":"Int. J. Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/s1359-6101(01)00032-6","article-title":"Interleukin-12 in anti-tumor immunity and immunotherapy.","volume":"13","author":"Colombo","year":"2002","journal-title":"Cytokine Growth Factor Rev."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11050677","article-title":"MAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma\/Myxofibrosarcoma.","volume":"11","author":"Conley","year":"2019","journal-title":"Cancers"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.4049\/jimmunol.1001965","article-title":"GM-CSF production by glioblastoma cells has a functional role in eosinophil survival, activation, and growth factor production for enhanced tumor cell proliferation.","volume":"187","author":"Curran","year":"2011","journal-title":"J. Immunol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1158\/1535-7163.MCT-16-0526","article-title":"Preclinical Evaluation of Sequential Combination of Oncolytic Adenovirus Delta-24-RGD and Phosphatidylserine-Targeting Antibody in Pancreatic Ductal Adenocarcinoma.","volume":"16","author":"Dai","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"B27","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/gt.2011.176","article-title":"Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4.","volume":"19","author":"Dias","year":"2012","journal-title":"Gene Ther."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19092694","article-title":"Targeting CD46 Enhances Anti-Tumoral Activity of Adenovirus Type 5 for Bladder Cancer.","volume":"19","author":"Do","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1002\/cncr.32909","article-title":"The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types.","volume":"126","author":"Einsele","year":"2020","journal-title":"Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/ijc.1556","article-title":"Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors.","volume":"94","author":"Elzey","year":"2001","journal-title":"Int. J. Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"5846","DOI":"10.1158\/1078-0432.CCR-17-0285","article-title":"Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus.","volume":"23","author":"Eriksson","year":"","journal-title":"Clin. Cancer Res."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2016.80","article-title":"Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment.","volume":"24","author":"Eriksson","year":"","journal-title":"Gene Ther."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17011-z","article-title":"Oncolytic virus-derived type I interferon restricts CAR T cell therapy.","volume":"11","author":"Evgin","year":"2020","journal-title":"Nat. Commun."},{"key":"B34","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1093\/jnci\/95.9.652","article-title":"Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway.","volume":"95","author":"Fueyo","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13744-8","article-title":"Artificially cloaked viral nanovaccine for cancer immunotherapy.","volume":"10","author":"Fusciello","year":"2019","journal-title":"Nat. Commun."},{"key":"B36","doi-asserted-by":"publisher","first-page":"31344","DOI":"10.18632\/oncotarget.5181","article-title":"The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic.","volume":"6","author":"Gabitzsch","year":"2015","journal-title":"Oncotarget"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12051139","article-title":"Expanding the Spectrum of Adenoviral Vectors for Cancer Therapy.","volume":"12","author":"Gao","year":"","journal-title":"Cancers"},{"key":"B38","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.omtm.2020.06.010","article-title":"Transient Chimeric Ad5\/37 Fiber Enhances NK-92 Carrier Cell-Mediated Delivery of Oncolytic Adenovirus Type 5 to Tumor Cells.","volume":"18","author":"Gao","year":"","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3313","article-title":"Delta-24-RGD, an Oncolytic Adenovirus, Increases Survival and Promotes Proinflammatory Immune Landscape Remodeling in Models of AT\/RT and CNS-PNET.","volume":"2020","author":"Garcia-Moure","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1080\/21645515.2017.1364322","article-title":"Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations.","volume":"13","author":"Gatti-Mays","year":"2017","journal-title":"Hum. Vaccin. Immunother."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0608","article-title":"A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA\/MUC1\/Brachyury)-Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer.","volume":"25","author":"Gatti-Mays","year":"2020","journal-title":"Oncologist"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1002\/eji.1830231037","article-title":"Molecular cloning of a ligand for the inducible T cell gene 4-1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor.","volume":"23","author":"Goodwin","year":"1993","journal-title":"Eur. J. Immunol."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1442169","article-title":"Heating it up: Oncolytic viruses make tumors \u2018hot\u2019 and suitable for checkpoint blockade immunotherapies.","volume":"7","author":"Gujar","year":"","journal-title":"Oncoimmunology"},{"key":"B44","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.it.2017.11.006","article-title":"Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies.","volume":"39","author":"Gujar","year":"","journal-title":"Trends Immunol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.virol.2009.07.010","article-title":"Defining the role of CD46, CD80 and CD86 in mediating adenovirus type 3 fiber interactions with host cells.","volume":"392","author":"Hall","year":"2009","journal-title":"Virology"},{"key":"B46","first-page":"727","article-title":"PD-1\/PD-L1 pathway: current researches in cancer.","volume":"10","author":"Han","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"B47","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.omto.2016.12.004","article-title":"Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy.","volume":"4","author":"Havunen","year":"2017","journal-title":"Mol. Ther. Oncolyt."},{"key":"B48","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","article-title":"Top 10 Challenges in Cancer Immunotherapy.","volume":"52","author":"Hegde","year":"2020","journal-title":"Immunity"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1038\/80474","article-title":"An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy.","volume":"6","author":"Heise","year":"2000","journal-title":"Nat. Med."},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2015.1074377","article-title":"A century of oncolysis evolves into oncolytic immunotherapy.","volume":"5","author":"Hemminki","year":"2016","journal-title":"Oncoimmunology"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1038\/mt.2012.115","article-title":"Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer.","volume":"20","author":"Hemminki","year":"2012","journal-title":"Mol. Ther."},{"key":"B52","doi-asserted-by":"publisher","first-page":"4467","DOI":"10.18632\/oncotarget.2901","article-title":"Immunological data from cancer patients treated with Ad5\/3-E2F-\u039424-GMCSF suggests utility for tumor immunotherapy.","volume":"6","author":"Hemminki","year":"2015","journal-title":"Oncotarget"},{"key":"B53","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nm.3089","article-title":"Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer.","volume":"19","author":"Heo","year":"2013","journal-title":"Nat. Med."},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aat9143","article-title":"Durable anticancer immunity from intratumoral administration of IL-23, IL-36\u03b3, and OX40L mRNAs.","volume":"11","author":"Hewitt","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1089\/hum.2014.069","article-title":"Immunological effects of a tumor necrosis factor alpha-armed oncolytic adenovirus.","volume":"26","author":"Hirvinen","year":"2015","journal-title":"Hum. Gene Ther."},{"key":"B56","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma.","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2016.64","article-title":"Stimulatory versus suppressive effects of GM-CSF on tumor progression in multiple cancer types.","volume":"48","author":"Hong","year":"2016","journal-title":"Exp. Mol. Med."},{"key":"B58","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/cgt.2010.5","article-title":"Potent antitumor effects of combined therapy with a telomerase-specific, replication-competent adenovirus (OBP-301) and IL-2 in a mouse model of renal cell carcinoma.","volume":"17","author":"Huang","year":"2010","journal-title":"Cancer Gene Ther."},{"key":"B59","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/cgt.2008.3","article-title":"Direct and distant antitumor effects of a telomerase-selective oncolytic adenoviral agent, OBP-301, in a mouse prostate cancer model.","volume":"15","author":"Huang","year":"2008","journal-title":"Cancer Gene Ther."},{"key":"B60","doi-asserted-by":"publisher","first-page":"3583","DOI":"10.1002\/1873-3468.13693","article-title":"Genomic foundations of evolution and ocular pathogenesis in human adenovirus species D.","volume":"593","author":"Ismail","year":"2019","journal-title":"FEBS Lett."},{"key":"B61","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/nrclinonc.2010.139","article-title":"Delivering nanomedicine to solid tumors.","volume":"7","author":"Jain","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"3894","DOI":"10.1158\/0008-5472.CAN-17-0468","article-title":"Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination.","volume":"77","author":"Jiang","year":"2017","journal-title":"Cancer Res."},{"key":"B63","doi-asserted-by":"publisher","first-page":"6801","DOI":"10.1158\/1078-0432.Ccr-19-0405","article-title":"Localized Treatment with Oncolytic Adenovirus Delta-24-RGDOX Induces Systemic Immunity against Disseminated Subcutaneous and Intracranial Melanomas.","volume":"25","author":"Jiang","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2019.100826","article-title":"Mystery eye: Human adenovirus and the enigma of epidemic keratoconjunctivitis.","volume":"76","author":"Jonas","year":"2020","journal-title":"Prog. Retin. Eye Res."},{"key":"B65","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.ymthe.2020.01.003","article-title":"Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody.","volume":"28","author":"Kanaya","year":"2020","journal-title":"Mol. Ther."},{"key":"B66","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1158\/1078-0432.CCR-12-2546","article-title":"Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus.","volume":"19","author":"Kanerva","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21596","article-title":"A review of cancer immunotherapy toxicity.","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"B68","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41568-019-0143-7","article-title":"The broken cycle: E2F dysfunction in cancer.","volume":"19","author":"Kent","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"B69","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/s0304-3835(02)00017-4","article-title":"Antitumoral effects of recombinant adenovirus YKL-1001, conditionally replicating in alpha-fetoprotein-producing human liver cancer cells.","volume":"180","author":"Kim","year":"2002","journal-title":"Cancer Lett."},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21072450","article-title":"Tumor Milieu Controlled by RB Tumor Suppressor.","volume":"21","author":"Kitajima","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B71","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.semcancer.2019.11.011","article-title":"Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer.","volume":"65","author":"Kobayashi","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/cgt.2009.33","article-title":"Conditional interleukin-12 gene therapy promotes safe and effective antitumor immunity.","volume":"16","author":"Komita","year":"2009","journal-title":"Cancer Gene Ther."},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11020198","article-title":"Rodents Versus Pig Model for Assessing the Performance of Serotype Chimeric Ad5\/3 Oncolytic Adenoviruses.","volume":"11","author":"Koodie","year":"2019","journal-title":"Cancers"},{"key":"B74","doi-asserted-by":"publisher","first-page":"9447","DOI":"10.1007\/s13277-014-2407-x","article-title":"Multifunctional CD40L: pro- and anti-neoplastic activity.","volume":"35","author":"Korniluk","year":"2014","journal-title":"Tumour Biol."},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01104","article-title":"Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.","volume":"9","author":"Kosti","year":"2018","journal-title":"Front. Immunol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"21248","DOI":"10.1073\/pnas.1015855107","article-title":"Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes.","volume":"107","author":"Kowanetz","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1532763","article-title":"Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model.","volume":"8","author":"Kuryk","year":"2019","journal-title":"Oncoimmunology"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1200\/JCO.2017.75.8219","article-title":"Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma.","volume":"36","author":"Lang","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1158\/1535-7163.MCT-19-0768","article-title":"Targeting Tumor Neoangiogenesis via Targeted Adenoviral Vector to Achieve Effective Cancer Gene Therapy for Disseminated Neoplastic Disease.","volume":"19","author":"Lee","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"B80","first-page":"2541","article-title":"Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production.","volume":"90","author":"Leonard","year":"1997","journal-title":"Blood"},{"key":"B81","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.2174\/0929867324666170804143706","article-title":"Immune Checkpoint Inhibitors: Basics and Challenges.","volume":"26","author":"Li","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"B82","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1128\/CMR.00116-13","article-title":"Adenovirus infections in immunocompetent and immunocompromised patients.","volume":"27","author":"Lion","year":"2014","journal-title":"Clin. Microbiol. Rev."},{"key":"B83","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.ymthe.2004.03.017","article-title":"An E1B-19 kDa gene deletion mutant adenovirus demonstrates tumor necrosis factor-enhanced cancer selectivity and enhanced oncolytic potency.","volume":"9","author":"Liu","year":"2004","journal-title":"Mol. Ther."},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02487-16","article-title":"Defining a Novel Role for the Coxsackievirus and Adenovirus Receptor in Human Adenovirus Serotype 5 Transduction in the Presence of Mouse Serum.","volume":"91","author":"Lopez-Gordo","year":"2017","journal-title":"J. Virol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/gt.2014.122","article-title":"Potent antitumor activity of Oct4 and hypoxia dual-regulated oncolytic adenovirus against bladder cancer.","volume":"22","author":"Lu","year":"2015","journal-title":"Gene Ther."},{"key":"B86","doi-asserted-by":"publisher","first-page":"7375","DOI":"10.1158\/1078-0432.CCR-09-1910","article-title":"Phase I clinical trial of an adenovirus\/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results.","volume":"15","author":"Lubaroff","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.Am2012-2692","article-title":"An ongoing Phase II trial of an adenovirus\/PSA vaccine for prostate cancer.","volume":"72","author":"Lubaroff","year":"2012","journal-title":"Cancer Res."},{"key":"B88","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.7150\/ijbs.34213","article-title":"Current Progress in CAR-T Cell Therapy for Solid Tumors.","volume":"15","author":"Ma","year":"2019","journal-title":"Int. J. Biol. Sci."},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0510-7","article-title":"A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE).","volume":"7","author":"Machiels","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/srep27598","article-title":"Dicer functions as an antiviral system against human adenoviruses via cleavage of adenovirus-encoded noncoding RNA.","volume":"6","author":"Machitani","year":"2016","journal-title":"Sci. Rep."},{"key":"B91","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.coi.2018.03.001","article-title":"Cancer vaccines: translation from mice to human clinical trials.","volume":"51","author":"Maeng","year":"2018","journal-title":"Curr. Opin. Immunol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1158\/1078-0432.CCR-19-2078","article-title":"Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study.","volume":"26","author":"Mahalingam","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"B93","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1089\/hum.2013.235","article-title":"Adenovirus-based vaccines for fighting infectious diseases and cancer: progress in the field.","volume":"25","author":"Majhen","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"B94","doi-asserted-by":"publisher","first-page":"MCB.105","DOI":"10.1128\/MCB.00105-19","article-title":"Deletion in Retinoblastoma Protein Pathway-Disrupted Cells Results in DNA Damage and Cancer Progression.","volume":"39","author":"Marshall","year":"2019","journal-title":"Mol. Cell Biol."},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10043-0","article-title":"The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models.","volume":"10","author":"Mart\u00ednez-V\u00e9lez","year":"2019","journal-title":"Nat. Commun."},{"key":"B96","doi-asserted-by":"publisher","first-page":"4633","DOI":"10.1245\/s10434-019-07691-3","article-title":"Efficacy of Talimogene Laherparepvec (T-VEC) Therapy in Patients with In-Transit Melanoma Metastasis Decreases with Increasing Lesion Size.","volume":"26","author":"Masoud","year":"2019","journal-title":"Ann. Surg. Oncol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1089\/hum.2004.15.1022","article-title":"Biology of adenovirus and its use as a vector for gene therapy.","volume":"15","author":"McConnell","year":"2004","journal-title":"Hum. Gene Ther."},{"key":"B98","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1001\/jamaoncol.2017.4408","article-title":"Carcinoembryonic Antigen-Still More to Learn From the Real World.","volume":"4","author":"Miksad","year":"2018","journal-title":"JAMA Oncol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s10555-019-09815-3","article-title":"Beyond the biomarker role: prostate-specific antigen (PSA) in the prostate cancer microenvironment.","volume":"38","author":"Moradi","year":"2019","journal-title":"Cancer Metastasis Rev."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1007\/s00262-013-1400-3","article-title":"Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients.","volume":"62","author":"Morse","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.575597","article-title":"Localized Interleukin-12 for Cancer Immunotherapy.","volume":"11","author":"Nguyen","year":"2020","journal-title":"Front. Immunol."},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11137-5","article-title":"Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy.","volume":"10","author":"Niemann","year":"2019","journal-title":"Nat. Commun."},{"key":"B103","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","article-title":"Cancer immunoediting and resistance to T cell-based immunotherapy.","volume":"16","author":"O\u2019Donnell","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-19300-6","article-title":"A hypoxia- and telomerase-responsive oncolytic adenovirus expressing secretable trimeric TRAIL triggers tumour-specific apoptosis and promotes viral dispersion in TRAIL-resistant glioblastoma.","volume":"8","author":"Oh","year":"2018","journal-title":"Sci. Rep."},{"key":"B105","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.urolonc.2017.07.005","article-title":"An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results.","volume":"36","author":"Packiam","year":"2018","journal-title":"Urol. Oncol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy.","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aat9321","article-title":"Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01.","volume":"11","author":"Pascual-Pasto","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"B108","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1002\/ijc.26216","article-title":"Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors.","volume":"130","author":"Pesonen","year":"2012","journal-title":"Int. J. Cancer"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1512329","article-title":"Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials.","volume":"8","author":"Pol","year":"2019","journal-title":"Oncoimmunology"},{"key":"B110","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2147\/OV.S154494","article-title":"Development and applications of oncolytic Maraba virus vaccines.","volume":"7","author":"Pol","year":"2018","journal-title":"Oncolyt. Virother."},{"key":"B111","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.ymthe.2020.02.016","article-title":"Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors.","volume":"28","author":"Porter","year":"2020","journal-title":"Mol. Ther."},{"key":"B112","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/nrd4534","article-title":"Unleashing the therapeutic potential of human kallikrein-related serine proteases.","volume":"14","author":"Prassas","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"B113","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/QCO.0000000000000451","article-title":"Human adenovirus infections: update and consideration of mechanisms of viral persistence.","volume":"31","author":"Radke","year":"2018","journal-title":"Curr. Opin. Infect. Dis."},{"key":"B114","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1158\/1078-0432.ccr-05-1059","article-title":"CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor\u2013armed oncolytic adenovirus for the treatment of bladder cancer.","volume":"12","author":"Ramesh","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-016-0121-5","article-title":"Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers.","volume":"4","author":"Ranki","year":"2016","journal-title":"J. Immunother. Cancer"},{"key":"B116","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.copbio.2007.10.010","article-title":"Replicating and non-replicating viral vectors for vaccine development.","volume":"18","author":"Robert-Guroff","year":"2007","journal-title":"Curr. Opin. Biotechnol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","article-title":"IL-2: the first effective immunotherapy for human cancer.","volume":"192","author":"Rosenberg","year":"2014","journal-title":"J. Immunol."},{"key":"B118","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1016\/j.ymthe.2017.09.010","article-title":"Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer.","volume":"25","author":"Rosewell Shaw","year":"2017","journal-title":"Mol. Ther."},{"key":"B119","doi-asserted-by":"publisher","first-page":"6875","DOI":"10.1128\/jvi.72.8.6875-6879.1998","article-title":"Circumvention of immunity to the adenovirus major coat protein hexon.","volume":"72","author":"Roy","year":"1998","journal-title":"J. Virol."},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aam7577","article-title":"Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade.","volume":"10","author":"Samson","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"B121","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1016\/j.ymthe.2018.06.001","article-title":"Adenovirus Coding for Interleukin-2 and Tumor Necrosis Factor Alpha Replaces Lymphodepleting Chemotherapy in Adoptive T Cell Therapy.","volume":"26","author":"Santos","year":"2018","journal-title":"Mol. Ther."},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000188","article-title":"Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity.","volume":"8","author":"Santos","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"B123","doi-asserted-by":"publisher","first-page":"8815","DOI":"10.1002\/jcb.28179","article-title":"Vaccines for colorectal cancer: an update.","volume":"120","author":"Sarvizadeh","year":"2019","journal-title":"J. Cell Biochem."},{"key":"B124","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy.","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"B125","first-page":"5420","article-title":"Reconstitution of endogenous interferon a by recombinant interferon in hairy cell leukemia.","volume":"60","author":"Shehata","year":"2000","journal-title":"Cancer Res."},{"key":"B126","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.cytogfr.2014.07.018","article-title":"The IL-2 cytokine family in cancer immunotherapy.","volume":"25","author":"Sim","year":"2014","journal-title":"Cytokine Growth Factor Rev."},{"key":"B127","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity.","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"2021","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"B129","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1038\/mt.2016.67","article-title":"Predictive and Prognostic Clinical Variables in Cancer Patients Treated With Adenoviral Oncolytic Immunotherapy.","volume":"24","author":"Taipale","year":"2016","journal-title":"Mol. Ther."},{"key":"B130","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1158\/0008-5472.CAN-16-1577","article-title":"Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors.","volume":"77","author":"Tanoue","year":"2017","journal-title":"Cancer Res."},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0772-z","article-title":"Tumor-derived exosomes, myeloid-derived suppressor cells, and tumor microenvironment.","volume":"12","author":"Tian","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.stem.2014.01.009","article-title":"CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis.","volume":"14","author":"Todaro","year":"2014","journal-title":"Cell Stem Cell"},{"key":"B133","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s00281-018-0691-z","article-title":"Therapeutic cancer vaccine: building the future from lessons of the past.","volume":"41","author":"Tran","year":"2019","journal-title":"Semin. Immunopathol."},{"key":"B134","doi-asserted-by":"publisher","first-page":"4225","DOI":"10.1016\/j.vaccine.2009.03.074","article-title":"In situ adenovirus vaccination engages T effector cells against cancer.","volume":"27","author":"Tuve","year":"2009","journal-title":"Vaccine"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0147211","article-title":"Characterization of the Antiglioma Effect of the Oncolytic Adenovirus VCN-01.","volume":"11","author":"Vera","year":"2016","journal-title":"PLoS One"},{"key":"B136","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1007\/s00535-012-0711-z","article-title":"Chimeric 5\/35 adenovirus-mediated Dickkopf-1 overexpression suppressed tumorigenicity of CD44+ gastric cancer cells via attenuating Wnt signaling.","volume":"48","author":"Wang","year":"2013","journal-title":"J. Gastroenterol."},{"key":"B137","doi-asserted-by":"publisher","first-page":"9536","DOI":"10.1016\/j.biomaterials.2011.08.069","article-title":"The transduction of Coxsackie and Adenovirus Receptor-negative cells and protection against neutralizing antibodies by HPMA-co-oligolysine copolymer-coated adenovirus.","volume":"32","author":"Wang","year":"2011","journal-title":"Biomaterials"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2270","article-title":"Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14.","volume":"17","author":"Wang","year":"2011","journal-title":"Nat. Med."},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01385-8","article-title":"Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent.","volume":"8","author":"Wang","year":"2017","journal-title":"Nat. Commun."},{"key":"B140","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1158\/1535-7163.MCT-07-2429","article-title":"A novel triple-regulated oncolytic adenovirus carrying p53 gene exerts potent antitumor efficacy on common human solid cancers.","volume":"7","author":"Wang","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"B141","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1038\/nbt887","article-title":"E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models.","volume":"21","author":"Wang","year":"2003","journal-title":"Nat. Biotechnol."},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0423-1","article-title":"New development in CAR-T cell therapy.","volume":"10","author":"Wang","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"B143","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/s12016-015-8498-3","article-title":"OX40, OX40L and Autoimmunity: a Comprehensive Review.","volume":"50","author":"Webb","year":"2016","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"B144","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41417-020-0176-9","article-title":"Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and\/or CD40.","volume":"2020","author":"Wenthe","year":"2020","journal-title":"Cancer Gene Ther."},{"key":"B145","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion.","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"B146","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1634\/theoncologist.2019-IO-S1-s05","article-title":"PD-1\/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.","volume":"24","author":"Xia","year":"2019","journal-title":"Oncologist"},{"key":"B147","doi-asserted-by":"publisher","first-page":"6747","DOI":"10.1158\/0008-5472.CAN-16-1404","article-title":"Recurrent Loss of STING Signaling in Melanoma Correlates with Susceptibility to Viral Oncolysis.","volume":"76","author":"Xia","year":"2016","journal-title":"Cancer Res."},{"key":"B148","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/cas.13228","article-title":"Recent advances in genetic modification of adenovirus vectors for cancer treatment.","volume":"108","author":"Yamamoto","year":"2017","journal-title":"Cancer Sci."},{"key":"B149","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1002\/jmv.23325","article-title":"Seroprevalence of neutralizing antibodies to human adenovirus type 5 in healthy adults in China.","volume":"84","author":"Yu","year":"2012","journal-title":"J. Med. Virol."},{"key":"B150","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1089\/hum.2016.022","article-title":"Epithelial Junction Opener Improves Oncolytic Adenovirus Therapy in Mouse Tumor Models.","volume":"27","author":"Yumul","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2020.222","article-title":"Oncolytic adenovirus type 3 coding for CD40L facilitates dendritic cell therapy of prostate cancer in humanized mice and patient samples.","volume":"2020","author":"Zafar","year":"","journal-title":"Hum. Gene Ther."},{"key":"B152","doi-asserted-by":"publisher","first-page":"00226","DOI":"10.1038\/s41417-020-00226-z","article-title":"Ad5\/3 is able to avoid neutralization by binding to erythrocytes and lymphocytes.","volume":"2020","author":"Zafar","year":"","journal-title":"Cancer Gene Ther."},{"key":"B153","first-page":"4570","article-title":"Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen.","volume":"57","author":"Zaremba","year":"1997","journal-title":"Cancer Res."},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0817-3","article-title":"Delivery strategies of cancer immunotherapy: recent advances and future perspectives.","volume":"12","author":"Zhao","year":"2019","journal-title":"J. Hematol. Oncol."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2021.707290\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T10:10:39Z","timestamp":1626862239000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2021.707290\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,21]]},"references-count":154,"alternative-id":["10.3389\/fmicb.2021.707290"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2021.707290","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,21]]},"article-number":"707290"}}